<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Thromboprophylaxis during pregnancy can be challenging when <z:chebi fb="5" ids="28304">heparin</z:chebi> is contraindicated </plain></SENT>
<SENT sid="1" pm="."><plain>Limited data exist regarding alternative <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> in the setting of pregnancy </plain></SENT>
<SENT sid="2" pm="."><plain>CASE: We present a patient with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> who developed <z:chebi fb="5" ids="28304">heparin</z:chebi>-induced <z:mp ids='MP_0005048'>thrombosis</z:mp> in the third trimester of pregnancy </plain></SENT>
<SENT sid="3" pm="."><plain>She was treated with therapeutic doses of intravenous lepirudin until delivery </plain></SENT>
<SENT sid="4" pm="."><plain>Induction of labor, regional anesthesia, and forceps-assisted vaginal delivery were performed with no fetal, neonatal, or maternal complications </plain></SENT>
<SENT sid="5" pm="."><plain>Postpartum, the patient was transitioned to <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy, and at 6 weeks postdelivery neither the patient nor her infant had developed any new problems </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Intravenous lepirudin use at therapeutic doses in late gestation as an alternative to <z:chebi fb="5" ids="28304">heparin</z:chebi> was accomplished with minimal maternal and fetal morbidity </plain></SENT>
</text></document>